Fulgent Genetics, Inc. Selected for Rapid Oral Presentation in Head & Neck Cancer Track at ASCO Annual Meeting 2026
Fulgent Genetics, Inc., a technology-driven company known for its established laboratory services and expanding therapeutic development pipeline, announced that one of its clinical research abstracts has been selected for presentation at the prestigious American Society of Clinical Oncology Annual Meeting 2026. This recognition highlights the company’s growing presence in oncology research and its commitment to advancing treatment options for patients with difficult-to-treat cancers.
The selected abstract will be featured as part of the Head and Neck Cancer Track within a Rapid Oral Abstract Session, a format reserved for high-impact and time-sensitive research findings. The session is scheduled to take place on June 1, 2026, between 4:30 PM and 6:00 PM Central Daylight Time (CDT). The presentation will be held in Hall D1 at McCormick Place in Chicago, one of the largest convention centers in the United States and a frequent host for major global medical conferences.
Study Overview and Scientific Focus
The abstract is titled:
“FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)” and is associated with the clinical trial identifier NCT06332092.
This study represents a Phase 2 clinical trial designed to evaluate multiple aspects of Fulgent’s investigational therapy, FID-007, when used in combination with cetuximab. The research focuses specifically on patients suffering from recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), a form of cancer that is particularly challenging to treat once it progresses beyond initial therapies.
The trial aims to:
- Assess the efficacy of different dosing regimens of FID-007
- Analyze pharmacokinetics (PK), which refers to how the drug is absorbed, distributed, metabolized, and eliminated in the body
- Evaluate safety and tolerability, ensuring that the treatment does not produce unacceptable side effects
Importantly, the study population includes patients whose disease has progressed after treatment with PD-L1-based immune checkpoint inhibitors. These patients typically have limited therapeutic options, making the development of new treatment strategies especially critical.
Clinical Significance
Head and neck squamous cell carcinoma is a serious and often aggressive cancer, particularly in its recurrent or metastatic stages. Standard treatments, including immunotherapy targeting PD-L1, have improved outcomes for some patients, but many still experience disease progression. This creates an urgent need for alternative therapies or combination approaches that can overcome resistance and improve survival.
FID-007, as an investigational agent, is being studied for its potential to enhance the effectiveness of cetuximab, a monoclonal antibody already used in the treatment of certain head and neck cancers. By combining these therapies, researchers hope to achieve better clinical outcomes than either treatment alone.
Leadership Perspective
Ming Hsieh, Chairman of the Board and Chief Executive Officer of Fulgent, expressed enthusiasm about the company’s selection for presentation at ASCO. He emphasized that being chosen for a rapid oral session is a significant honor, reflecting the scientific importance and potential clinical impact of the research.
He noted that the company is encouraged by the interim Phase 2 data observed so far and remains optimistic about FID-007’s potential as a treatment option for patients with recurrent or metastatic HNSCC. According to him, this patient population currently faces a shortage of effective therapies, making innovation in this space both necessary and urgent.
Presentation Details
The presentation will include contributions from a team of respected oncology researchers and clinicians. The primary presenter will be:
- Guilherme Rabinowits, MD, a senior member of the Head and Neck-Endocrine Oncology Department at Moffitt Cancer Center
Additional authors contributing to the study include:
- Christine H. Chung
- Aditya Shreenivas
- Eric S. Nadler
- Donald A. Richards
- Nabil F. Saba
- Ray Yin
- Jorge J. Nieva
- Jacob S. Thomas
The abstract has been assigned the identification number #6020 for the conference.
Availability of Research Materials
Attendees and interested stakeholders will be able to access the abstract on the official ASCO website starting May 21, 2026, at 5:00 PM Eastern Standard Time (EST). Additionally, the full presentation will be made available on Fulgent’s investor relations website at the beginning of the session on June 1, allowing broader access to the findings beyond conference attendees.
Broader Context
The ASCO Annual Meeting is one of the most influential oncology conferences globally, bringing together leading researchers, clinicians, and industry experts to share the latest advances in cancer research and treatment. Being selected for a rapid oral presentation indicates that Fulgent’s study is considered both timely and impactful within the oncology community.
For Fulgent, this milestone underscores its transition from a diagnostics-focused company to a more integrated healthcare organization with a growing footprint in therapeutic innovation. The company’s efforts in oncology drug development reflect a broader industry trend toward precision medicine and targeted therapies.
Fulgent’s upcoming presentation at ASCO 2026 represents an important step in the clinical development of FID-007 and highlights the company’s commitment to addressing unmet medical needs in oncology. With promising interim data and a focus on patients with limited treatment options, the study could contribute valuable insights into new combination strategies for managing advanced head and neck cancers.
As the oncology field continues to evolve, collaborations between research institutions, clinicians, and biotech companies like Fulgent will play a critical role in bringing innovative therapies to patients who need them most.
About Fulgent
Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a diagnostic business into a fully integrated precision medicine company.
